Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel
The Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel is a noninvasive blood test that combines age, AST, ALT, and platelet count to estimate the risk of advanced liver fibrosis, including bridging fibrosis and cirrhosis. It may be used as an initial assessment for people with MASLD (formerly NAFLD), chronic hepatitis B or C, elevated liver enzymes, or metabolic risk factors for fatty liver disease.
- $19.45
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Alt
AST
FIB 4 INDEX
FIB 4 INTERPRETATION
FIB 4 SUMMARY
Platelet Count
The Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel test contains 1 test with 6 biomarkers .
Liver fibrosis is the buildup of scar tissue caused by ongoing liver injury. When fibrosis progresses to advanced stages—F3 bridging fibrosis or F4 cirrhosis—the risk of serious liver-related complications increases. Because liver fibrosis may develop without obvious symptoms, a noninvasive assessment can help determine whether additional evaluation may be appropriate.
The Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel measures aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count. These laboratory results are combined with the patient’s age to calculate the FIB-4 Index:
FIB-4 Index = Age × AST ÷ [Platelet Count × √ALT]
The resulting score estimates the likelihood that advanced liver fibrosis is present. A lower FIB-4 Index is generally more consistent with the absence of advanced fibrosis, while an elevated score is more consistent with an increased likelihood of advanced fibrosis. An indeterminate or elevated result may lead to additional assessment with transient elastography, the Enhanced Liver Fibrosis (ELF) test, other imaging, or evaluation by a gastroenterologist or hepatologist.
FIB-4 is commonly used as an initial risk-stratification tool for adults with suspected or established metabolic dysfunction-associated steatotic liver disease, formerly called nonalcoholic fatty liver disease. It may also be used when evaluating fibrosis risk in people with chronic hepatitis B or hepatitis C. The appropriate interpretation and follow-up depend on the underlying liver condition, age, medical history, and other clinical findings.
This Panel May Be Appropriate For People Who Have
- Fatty liver or hepatic steatosis identified on an imaging study
- Metabolic dysfunction-associated steatotic liver disease, formerly NAFLD
- Suspected metabolic dysfunction-associated steatohepatitis, formerly NASH
- Prediabetes or type 2 diabetes
- Obesity, increased waist circumference, or metabolic syndrome
- Abnormal or persistently elevated AST or ALT levels
- Chronic hepatitis B or hepatitis C
- Dyslipidemia or other metabolic risk factors associated with fatty liver disease
- A need for an initial, noninvasive assessment of advanced liver fibrosis risk
FIB-4 is especially useful as a first-step assessment that can help identify people who may benefit from more specific liver fibrosis testing or specialist evaluation.
What Is Included
Aspartate Aminotransferase — AST
AST is an enzyme found in the liver, muscles, and several other tissues. Increased AST may occur with liver injury, but it is not specific to the liver. The AST result is one of the laboratory values used to calculate the FIB-4 Index.
Alanine Aminotransferase — ALT
ALT is an enzyme found primarily in the liver. Increased ALT may indicate liver-cell injury or inflammation. The ALT result is incorporated into the FIB-4 calculation.
Platelet Count
This test measures the number of platelets in the blood. Platelet levels can decline in some people with advanced chronic liver disease, although a low platelet count may also result from medications, infections, immune conditions, and other causes.
FIB-4 Index
The FIB-4 Index is calculated using the patient’s age, AST, ALT, and platelet count. It provides a single score that helps estimate the likelihood of advanced liver fibrosis.
Understanding the Results
| FIB-4 result category | What it may indicate | Possible next step |
|---|---|---|
| Lower score | More consistent with the absence of advanced liver fibrosis | Periodic reassessment may be recommended when risk factors remain |
| Indeterminate score | The result does not clearly place the person in a lower- or higher-risk category | Additional noninvasive testing, such as transient elastography or ELF, may be recommended |
| Higher score | More consistent with an increased likelihood of advanced fibrosis | Confirmation with additional testing and clinical evaluation may be appropriate |
The numerical thresholds used to interpret FIB-4 are not identical for MASLD, hepatitis B, and hepatitis C. Age can also affect interpretation, particularly in adults older than 65. Results should therefore be evaluated using the interpretive information on the laboratory report and the person’s clinical circumstances.
Important Limitations
The FIB-4 Index is a risk-assessment tool, not a definitive diagnosis. It does not directly measure liver stiffness, determine the exact fibrosis stage, identify the cause of liver injury, or independently diagnose fatty liver disease, MASH/NASH, cirrhosis, viral hepatitis, or liver cancer.
AST, ALT, and platelet count can be affected by conditions unrelated to liver fibrosis. Acute illness, alcohol exposure, muscle injury, medications, viral infections, immune platelet disorders, and other factors may increase or decrease the FIB-4 score. FIB-4 may also be less reliable in adults younger than 35 and requires age-adjusted interpretation in adults older than 65.
A low result cannot completely exclude advanced fibrosis, and a high result does not prove that advanced fibrosis is present. Unexpected, indeterminate, or elevated results should be discussed with a qualified healthcare professional.
Panel scope: This focused panel includes AST, ALT, platelet count, and the calculated FIB-4 Index. It is not a comprehensive liver function panel and does not include bilirubin, alkaline phosphatase, albumin, total protein, or viral hepatitis testing.
Patient Preparation
No special patient preparation is specified. Follow any preparation instructions provided for other tests ordered at the same time. Inform the healthcare professional interpreting the results about medications, supplements, recent illness, alcohol use, strenuous exercise, and any condition that may affect liver enzymes or platelet count.
Methodology
- AST and ALT: Spectrophotometry
- Platelet Count: Electronic sizing and counting, cytometry, and/or microscopy
- FIB-4 Index: Calculated from patient age, AST, ALT, and platelet count